ZPHC Pharmaceutical and Somatropin Zptropin
The Board of Directors (the “Board”) of ZPHC Pharmaceutical (“the Company” or “ZPHC Pharmaceutical” together with its subsidiaries – the “Group”) declares that Moson Koral International (HK) Ltd., in full (“Agreements”) with the Austrian pharmaceutical company Trolma-Pharma GmbH (“Trolma-Pharma”) are to create a joint venture ZPHC Aesthetic & Cosmetic and the release of the updated product of Somatropin Zptropin.
ZPHC mainly deals with the marketing of minimally invasive aesthetic products. As part of the joint venture agreement, the Group will provide its knowledge of multi-channel distribution and marketing in Asia.
Applicable interest rates for the above transaction are less than 5%. This announcement is made by the Company on a voluntary basis, to enable the investment community to understand the development of business in recent years and does not constitute an advertisement regarding the use of any drug, surgical device, treatment or orally consumed product.